8-KRegulation FD

Elevance Health, Inc. 8-K Report, Regulation FD Disclosure (Jun 10, 2026)

Filed June 10, 2026For Securities:ELV

Summary

Elevance Health, Inc. (ELV) issued an 8-K filing on June 10, 2026, to reaffirm its financial guidance for the full year 2026. The company expects shareholders' earnings per diluted share to be at least $19.85, which includes approximately $6.90 per diluted share from net unfavorable items. Excluding these items, the adjusted shareholders' earnings are projected to be at least $26.75 per diluted share, consistent with expectations set in the first quarter of 2026. This guidance does not incorporate any further adjustment items beyond those already reported. Additionally, Elevance Health is reiterating its full-year 2026 guidance for the benefit expense ratio, which is expected to be 90.2% plus or minus 50 basis points. This filing serves as a communication with investors and analysts, confirming the company's financial outlook and operational expectations for the remainder of the fiscal year.

Key Highlights

  • 1Reaffirmed full-year 2026 shareholders' earnings guidance of at least $19.85 per diluted share.
  • 2Confirmed adjusted shareholders' earnings guidance of at least $26.75 per diluted share for full-year 2026.
  • 3Net unfavorable items are expected to impact earnings by approximately $6.90 per diluted share for 2026.
  • 4Reiterated full-year 2026 benefit expense ratio guidance of 90.2% +/- 50 basis points.
  • 5Guidance reaffirms previously stated financial expectations and does not include new adjustment items beyond Q1 2026.
  • 6Filing is a Regulation FD disclosure intended for investor and analyst meetings.
  • 7Standard forward-looking statements disclaimer included, highlighting potential risks and uncertainties.

Frequently Asked Questions

The primary purpose of this 8-K filing is for Elevance Health, Inc. to reaffirm its previously issued financial guidance for the full fiscal year 2026 to investors and analysts during upcoming meetings.

Elevance Health is reaffirming its guidance for full-year 2026 shareholders' earnings to be at least $19.85 per diluted share. This includes approximately $6.90 per diluted share from net unfavorable items. Excluding these items, the adjusted earnings per diluted share are expected to be at least $26.75.

The company is also reaffirming its full-year 2026 guidance for the benefit expense ratio, projecting it to be 90.2% plus or minus 50 basis points.

No, this filing specifically states that the company is reaffirming its existing guidance and that it does not include any other adjustment items beyond those reported in the first quarter of 2026. The forward-looking statements section outlines potential risks but does not introduce new financial guidance.